Pregnanediol
(Synonyms: 孕二醇; NSC 1612; NSC 47462) 目录号 : GC39185
Pregnanediol 是一种内源性代谢产物。
Cas No.:80-92-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Pregnanediol is an endogenous metabolite.
| Cas No. | 80-92-2 | SDF | |
| 别名 | 孕二醇; NSC 1612; NSC 47462 | ||
| Canonical SMILES | C[C@@]12[C@]3([H])[C@](CC[C@]1([H])C[C@H](O)CC2)([H])[C@@]4([H])[C@@](C)([C@]([C@@H](O)C)([H])CC4)CC3 | ||
| 分子式 | C21H36O2 | 分子量 | 320.51 |
| 溶解度 | Ethanol: 5 mg/mL (15.60 mM); DMSO: 2 mg/mL (6.24 mM); Water: < 0.1 mg/mL (insoluble) | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.12 mL | 15.6001 mL | 31.2003 mL |
| 5 mM | 0.624 mL | 3.12 mL | 6.2401 mL |
| 10 mM | 0.312 mL | 1.56 mL | 3.12 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Direct measurement of Pregnanediol 3-glucuronide (PDG) in dried urine spots by liquid chromatography-mass spectrometry to detect ovulation
J Steroid Biochem Mol Biol 2021 Jul;211:105900.PMID:33872762DOI:10.1016/j.jsbmb.2021.105900.
Background: Non-invasive self-testing using an objective chemical method to detect ovulation is valuable for women planning conception, practising contraception or undergoing infertility investigations or treatment. Methods: Based on luteal phase secretion of progesterone (P4) and excretion of its major metabolite, Pregnanediol glucuronide (PDG), we developed a novel direct liquid chromatography-mass spectrometry (LCMS) method to measure PDG and other steroid glucuronides in urine and in dried urine spots (DUS) without deconjugation or derivatization. Urine PDG by LCMS and immunoassay (P3G) and P4 by immunoassay with and without adjustment for creatinine were evaluated in daily first void urine samples from 10 women through a single menstrual cycle in which ovulation was confirmed by serial transvaginal ultrasound. Results: Urine PDG with and without creatinine adjustment was stable during the follicular phase with the expected striking rise in the luteal phase peaking at 5 days after ovulation. Using a single spot urine sample (100 μL) or a DUS (<20 μL urine) and an optimal threshold to distinguish pre- from post-ovulatory samples, in ROC analysis urine PDG adjusted for creatinine accurately identified ovulation in 92 % of samples was comparable with P3G immunoassay and superior to urine P4 with or without adjustment for creatinine. Extending the analysis to two or three consecutive daily samples reduced the false negative rate from 8% to 2.6 % for two and 1.9 % for three urine samples. Conclusions: This method holds promise as a non-invasive self-test method for women to determine by an objective chemical method their ovulatory status.
Rapid measurement of urinary Pregnanediol glucuronide to diagnose ectopic pregnancy
Am J Obstet Gynecol 1988 Dec;159(6):1531-5.PMID:3061300DOI:10.1016/0002-9378(88)90589-3.
We investigated the ability of a single, random, urinary pregnanediol-3 alpha-glucuronide level to differentiate early intrauterine from ectopic pregnancy. Thirty-four patients with intrauterine gestations were compared with 60 patients with ectopic pregnancies. Urinary pregnanediol-3 alpha-glucuronide was measured by radioimmunoassay and enzyme immunoassay. Compared with intrauterine gestations, results demonstrate that urinary pregnanediol-3 alpha-glucuronide is significantly depressed in ectopic pregnancies: 24.5 +/- 2.2 versus 4.8 +/- 0.7 micrograms/ml (p = 0.0001). Urinary pregnanediol-3 alpha-glucuronide levels obtained by conventional radioimmunoassay correlated closely with values measured in minutes with enzyme immunoassay (r = 0.95, p = 0.0001), and with serum progesterone (r = 0.74, p = 0.0001). Urinary pregnanediol-3 alpha-glucuronide measured by enzyme immunoassay exhibited predictive values for detecting ectopic gestations comparable with random serum progesterone or serum beta-human chorionic gonadotropin values. We conclude that ectopic gestations demonstrate a reduced level of urinary pregnanediol-3 alpha-glucuronide (55/60 cases) detectable with a rapid enzyme immunoassay, which makes this assay a practical screening test in early pregnancy.
Hormonal Smartphone Diagnostics
Methods Mol Biol 2018;1735:505-515.PMID:29380341DOI:10.1007/978-1-4939-7614-0_38.
Mobile point-of-care diagnostics are paramount for the provision of healthcare. Hormonal diagnostics are powerful tools to monitor timely changes in human physiology. Hormone concentrations in serum directly correlate with urine excretions with minor time delays. Therefore, rapid tests for hormones in urine have been widely used for decades as means of early diagnostics, particularly in lateral flow immunoassay formats. However, the challenge of reading and interpreting these binary tests remains. Here we present a method for utilizing mobile technologies to quantitatively read and interpret hormonal test strips. The method demonstrates the detection of a urinary by-product of progesterone, Pregnanediol glucuronide (PdG), and its relation to ovulation and the fertility cycle.
Use of urinary Pregnanediol 3-glucuronide to confirm ovulation
Steroids 2013 Oct;78(10):1035-40.PMID:23831784DOI:10.1016/j.steroids.2013.06.006.
Objective: Urinary hormonal markers may assist in increasing the efficacy of Fertility Awareness Based Methods (FABM). This study uses urinary pregnanediol-3a-glucuronide (PDG) testing to more accurately identify the infertile phase of the menstrual cycle in the setting of FABM. Methods: Secondary analysis of an observational and simulation study, multicentre, European study. The study includes 107 women and tracks daily first morning urine (FMU), observed the changes in cervical mucus discharge, and ultrasonography to identify the day of ovulation over 326 menstrual cycles. The following three scenarios were tested: (A) use of the daily pregnandiol-3a-glucuronide (PDG) test alone; (B) use of the PDG test after the first positive urine luteinizing hormone (LH) kit result; (C) use of the PDG test after the disappearance of fertile type mucus. Two models were used: (1) one day of PDG positivity; or (2) waiting for three days of PDG positivity before declaring infertility. Results: After the first positivity of a LH test or the end of fertile mucus, three consecutive days of PDG testing over a threshold of 5μg/mL resulted in a 100% specificity for ovulation confirmation. They were respectively associated an identification of an average of 6.1 and 7.6 recognized infertile days. Conclusions: The results demonstrate a clinical scenario with 100% specificity for ovulation confirmation and provide the theoretical background for a future development of a competitive lateral flow assay for the detection of PDG in the urine.
Relationship of Pregnanediol level to cognitive behavior and mood
Psychosom Med 1985 Jan-Feb;47(1):26-34.PMID:3975325DOI:10.1097/00006842-198501000-00003.
This work examines data secured from a larger study relating cognitive behavior and mood in women to variation in estrogen level. The larger study noted that performance tended to be better during the luteal phase. The present analysis looks at the relationship of urinary Pregnanediol levels with mood and cognitive behaviors. Thirty women with non-oral contraceptive-controlled menstrual cycles were tested during the luteal phase on a battery of cognitive tests and a variation of the Clyde Mood Scale. The cognitive tests were selected based upon the automatization versus perceptual restructuring dimensions described by Broverman and colleagues. Pregnanediol levels were measured in 24-hour urine specimens collected on the same day. Results show a significant relationship of Pregnanediol level with mental subtraction and with time estimation. Perceptual restructuring tasks in general (perceptual restructuring index) showed a significant positive relationship with Pregnanediol levels. Mood, however, was not found to be related to Pregnanediol levels.